Wall Street Journal, July 9, 2021: Drug prices in the US are extremely high with both sides of the aisle advocating for Medicare to be able to negotiate drug prices. Dr. Diana Zuckerman spoke with the WSJ about how President Biden plans to lower drug prices.
Read More »Author: Caroline Bradford
Emergency Use Authorization vs. Full Approval: What are the Implications?
Contagion Live, June 20, 2021: What is the difference between Emergency Use Authorization and FDA Approval? Dr. Diana Zuckerman addresses the difference between the two and the implications of both.
Read More »New Alzheimer’s drug could be ‘devastating’ for Medicare
Politico, June 15, 2021: The controversial approval of the first drug to target Alzheimer’s disease in nearly 20 years has been blasted by many experts, because the drug is not proven to work and will cost $56,000 per year. “You don’t have to be a rocket scientist to know that the impact on Medicare is likely to be devastating,” said Diana Zuckerman, the president of the National Center for Health Research.
Read More »Alzheimer’s drug approval debacle deepens FDA scrutiny
Politico, June 11, 2021: Dr. Diana Zuckerman speaks with Politico on the impact that the newly approved Alzheimer’s drug will have on Democratic senators.
Read More »Statement of Dr. Diana Zuckerman on FDA’s Approval of Alzheimer’s Drug Aduhelm
June 8, 2021: Dr. Diana Zuckerman, president of NCHR, speaks out against FDA’s approval of the ineffective Alzheimer’s drug aduhelm.
Read More »